Worldwide: Life Sciences, Biotechnology & Nanotechnology

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

One-Way NDA vs. Mutual NDA For Life Sciences And Other Technology Companies: A Founder's Decision Guide

When you need to share sensitive information with a potential investor or business partner, a nondisclosure agreement ("NDA"), sometimes called a confidential disclosure agreement, is often the first contract on the table.

United States IP

C

Crowley Law LLC

FDA Announces Third Year Of Voluntary Quality Management Maturity (QMM) Prototype Assessment Program

On February 11, 2026, the U.S. Food and Drug Administration (FDA or the Agency) published a Federal Register notice announcing an opportunity for nine drug manufacturing establishments to participate...

United States Healthcare

AP

Arnold & Porter

MHRA Launches Targeted Consultation On Indefinite Recognition Of CE‑Marked Medical Devices

Today, 16 February 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) opened an important consultation seeking views on proposed changes to the recognition of CE‑marked medical devices...

United States Healthcare

AP

Arnold & Porter

"The Great American Recovery Initiative": What President Trump's New Executive Order Means For Behavioral Health Providers

On January 29, 2026, President Trump signed Executive Order 14379, titled: "Addressing Addiction Through the Great American Recovery Initiative" (Executive Order).

United States Healthcare

FL

Foley & Lardner

"Innovation: The Intersection Of Biotech, Patent Law, And AI With Dr. Kate Neville, IP Attorney"

United States IP

MG

Marshall, Gerstein & Borun LLP

Shareholder Activism In Life Sciences: Risks, Responses, And Outlook

United States Commercial

GP

Goodwin Procter LLP

Leaders In Law: Life Sciences And Technology Transactions With Jekkie Kim (Video)

United States Healthcare

W

WilmerHale

Leaders In Law: Life Sciences And Technology Transactions With Jekkie Kim (Podcast)

United States Healthcare

W

WilmerHale

FDA Announces New Enforcement Policy On "No Artificial Colors" Food Labeling

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

NSF Will Establish National Quantum And Nanotechnology Research Infrastructure; Letters Of Intent Are Due March 16, 2026

United States Healthcare

BC

Bergeson & Campbell

Life Sciences Dealmaking Accelerates In 2026: Key Insights From EY's Firepower M&A Report

United States Healthcare

SR

McDermott Will & Schulte

Genetic Testing Enforcement Poised To Rise: What To Expect In The Coming Year

United States Healthcare

KM

Katten Muchin Rosenman LLP

Samsung And Regeneron Settle Aflibercept BPCIA Case

United States Healthcare

GP

Goodwin Procter LLP

Reforms To FDA Requirements For Cell And Gene Therapy Products

United States Healthcare

GP

Goodwin Procter LLP

What Europe's Renewable Energy Struggles Can Teach U.S. Regulators About Dispute System Design

United States Litigation

J

JAMS

SECURE 2.0: Key Provisions And Tax Planning Implications For American Retirees

United States Tax

RS

Rotfleisch & Samulovitch P.C.

Simpson Thacher Sustainability And ESG: Regulatory Update – January 2026

Worldwide Environment

ST

Simpson Thacher & Bartlett

Signed, Sealed, But Not Delivered? Don't Wonder About Taxes Under New Postal Service Rules

United States Tax

N

Nossaman LLP

Congress Proposes Major Overhaul Of WARN: What Employers Need To Know About The Fair Warning Act

United States Employment

PR

Proskauer Rose LLP

Oliver Twisted Again: After FDA's Court Losses, Congress Approves FDA's Standards On Orphan Drug Exclusivity

Last week, Congress enacted the Consolidated Appropriations Act of 2026. This legislation narrows the scope of the statutory protection for drugs for rare diseases and conditions under the Orphan Drug Act, 21 U.S. Code § 360cc.

United States Healthcare

AV

Axinn Veltrop & Harkrider

2026 Top-of-Mind Issues For Life Sciences Companies

Every so often, a moment occurs that shifts the tectonic plates of an industry.

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

J.P. Morgan Healthcare Conference 2026: Recap And What To Watch

Attorneys from Ballard Spahr's Life Sciences and Health Care Industry Teams descended upon sunny San Francisco for the 44th Annual J.P. Morgan Health Care Conference—#JPM26—January 12 to 15.

United States Healthcare

BS

Ballard Spahr LLP

2026 Global Corporate Practice Transaction Highlights

Our 2026 Global Corporate Practice Transaction Highlights publication presents a comprehensive overview of significant deals executed across our global platform over the past year.

United States Commercial

KG

K&L Gates LLP

PBM Reform Cheat Sheet: Chart Comparing The Recent Rules For Group Plans

United States Employment

FL

Foley & Lardner

FDA Launches Manufacturing PreCheck Pilot Program To Boost U.S. Drug Production

United States Healthcare

LB

Lewis Brisbois Bisgaard & Smith LLP

The Regulatory Roadmap: Five Critical Questions For Evaluating Regulatory Risk For Longevity Companies

United States Healthcare

AF

ArentFox Schiff

Benesch's Dental/DSO Intelligence Monthly Report: February 2026

United States Healthcare

B

Benesch Friedlander Coplan & Aronoff LLP

Regulatory Horizons: Cybersecurity And FDA Regulated Companies (Podcast)

United States Healthcare

B

BakerHostetler

Oral Semaglutide And The GLP-1 Compounding Reckoning: From Regulatory Ambiguity To FDA Enforcement, DOJ Referrals, And Novo Nordisk's Case Against Hims & Hers

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

Congress Passes Landmark PBM Reform In 2026 Spending Bill

United States Healthcare

M

Mintz

Here We Go Again: Third Round Of Inflation Reduction Act Drugs Listed

United States Healthcare

AV

Axinn Veltrop & Harkrider

Healthy AI: 2025 Year In Review

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

Is The Government's Claim To University Patent Royalties A Better Deal For Taxpayers And Innovation?

United States IP

CG

Cahill Gordon & Reindel LLP

Congress Passes Landmark PBM Reform In 2026 Spending Bill

On February 3, 2026, Congress passed – and the President signed – the Consolidated Appropriations Act, 2026 (2026 CAA). The legislation includes a long‑anticipated and far‑reaching package of PBM reforms.

United States Healthcare

M

Mintz

Here We Go Again: Third Round Of Inflation Reduction Act Drugs Listed

Pursuant to the Inflation Reduction Act (the "IRA"), the Secretary of Health and Human Services ("HHS") and the Center for Medicare & Medicaid Services ("CMS") have begun the annual process of negotiating with pharmaceutical companies regarding the price of certain drugs covered under Medicare Part D and Part B in an attempt to reduce drug prices.

United States Healthcare

AV

Axinn Veltrop & Harkrider

Healthy AI: 2025 Year In Review

This publication provides an overview of important developments at the intersection of AI, healthcare and the law in 2025.

United States Healthcare

SM

Sheppard, Mullin, Richter & Hampton LLP

Is The Government's Claim To University Patent Royalties A Better Deal For Taxpayers And Innovation?

A recent proposal by Commerce Secretary Howard Lutnick that the federal government claim up to 50% of royalties from university-owned patents...

United States IP

CG

Cahill Gordon & Reindel LLP

Genentech/Hoffmann La-Roche And Shanghai Henlius Biotech/Organon Settle Pertuzumab BPCIA Case

United States Healthcare

GP

Goodwin Procter LLP

2026 US Health Care Policy Outlook: Affordability Pressures, TrumpRx, And ACA Uncertainty

Health care policy will be at the center of Washington's agenda in 2026. The midterm elections this November are already shaping the federal landscape and influencing Congress's priorities.

United States Healthcare

M

Mintz

DOJ And HHS-OIG Report A Record Year Of Enforcement, With Healthcare Fraud At The Center

The U.S. Department of Justice (DOJ)'s Criminal Division Fraud Section closed 2025 with what it characterized as a "record-setting" year, marked by a renewed emphasis on corporate enforcement...

United States Healthcare

AP

Arnold & Porter

Holland & Knight Health Dose: February 10, 2026

U.S. Congress will largely return to normal operations this week, following passage of an appropriations package on February 3, 2026, that will fund the vast majority of federal agency...

United States Healthcare

HK

Holland & Knight

Compensation Considerations For Health System Innovation Activities (Podcast)

This special series of the Governing Health podcast with SullivanCotter highlights developments in and offers support to the board's executive compensation committee in light...

United States Healthcare

SR

McDermott Will & Schulte

The Eyes Have It: FDA Approves Phase 1 Clinical Trial Of Life Biosciences' Reprogramming Therapy For Vision Loss

United States Healthcare

AF

ArentFox Schiff

Delaware Law Alert: New Perspectives On Earnouts

United States Commercial

MB

Mayer Brown

Inside HPE Europe 2025 | The Future Of Life Sciences Investment

Worldwide Healthcare

SR

McDermott Will & Schulte

Pay Transparency + The Power Of Preventive Strategies: Episode 3 — Pivoting Toward Preparation In The Life Sciences (Video)

United States Healthcare

JL

Jackson Lewis P.C.

US Policy Is Disrupting The Global Pharmaceutical Industry

Worldwide Healthcare

SR

McDermott Will & Schulte

OECD Paper Compares Regulatory Environments For Biotechnology And Biosolutions Between The EU And United States

Worldwide Healthcare

BC

Bergeson & Campbell

Outlook 2026: Texas Health Care

United States Healthcare

GT

Greenberg Traurig, LLP

A Strategic Approach To Legal Services For Biotech Startups

United States Technology

FL

Fennemore

The EU Medical Device Shake‑Up: What International Companies Should Prepare For

United States Healthcare

AP

Arnold & Porter

Congress Probes Chinese Biotech GLP-1 Product Compliance

United States Healthcare

KM

Katten Muchin Rosenman LLP

NSCEB Paper Outlines Policy Options To Modernize Oversight Of Biotechnology Products

United States Healthcare

BC

Bergeson & Campbell

FDA's Draft Guidance For Cosmetics Industry Explains Records-Access Authority During Inspections

United States Healthcare

WR

Wiley Rein

Health Headlines: January 2026

United States Healthcare

GP

Goodwin Procter LLP

Virtual And Digital Health Digest – December 2025

United States Healthcare

AP

Arnold & Porter

New Draft Guidance Addresses FDA's Records Access Authority For Cosmetics Under MoCRA

United States Healthcare

AF

ArentFox Schiff

See more

Highlighted Content

Plausibility At The EPO – An Update On G2/21

United States Healthcare

D

Dehns

Infringement Of Repurposed Drug Patents And Skinny Labelling – Where Does The Balance Lie In The United States Today?

United States Healthcare

D

Dehns

Infringement Of Repurposed Drug Patents And Skinny Labelling – Where Does The Balance Lie In Europe Today?

United States Healthcare

D

Dehns

How Good Does A Copy Need To Be?

United States Healthcare

D

Dehns

Supplementary Protection Certificates – European Patent Term Extensions

United States Healthcare

D

Dehns

How Much Experimental Data Is Needed For Patent Applications In Europe?

United States Healthcare

D

Dehns

Implications Of The Genetic Technology (Precision Breeding) Bill On The Life Science IP Sector

United States Healthcare

D

Dehns

Protection For Plant Varieties In Europe And The UK Post-Brexit

United States Healthcare

D

Dehns

Best Practice For Invention Harvesting

United States Healthcare

D

Dehns

ADR And Diversity In The Life Sciences Sector

United States Commercial

J

JAMS

Latest Videos

See more

Pay Transparency + The Power Of Preventive Strategies: Episode 3 — Pivoting Toward Preparation In The Life Sciences (Video)

JL

Jackson Lewis P.C.

Episode 37: Chanda Center For Health: Reimagining Access To And Delivery Of Long-term Disability Care (Podcast)

FL

Foley & Lardner

Critical Medical Device Series: Part X Balancing Risk And Innovation: Fraud And Abuse Trends For MedTech (Video)

AP

Arnold & Porter

Non-binding Guidance: The Administration's Focus On Direct-to-Consumer Prescription Drug Advertising (Podcast)

RG

Ropes & Gray LLP

Inside MedTech Translation Challenges: Ensuring Multilingual Regulatory Compliance

Moringside

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More